This was inspired by an articl reprint
Initiator/subject
Product/Activity
Increased
Product/Activity Decreased
Journal/Volume /Page
Author/Year
metab syndrome/cure /prevention of/ DM/HTN
life
death
Diabetes Research andClinical Practice/Volume 79/Issue 3/Pages 461-467
Pai-Feng Hsua/Shao-Yuan Chuang/Hao-Min Cheng/08
Diabetes Research and Clinical Practice Volume 79, Issue 3, March 2008, Pages 461-467
Clinical significance of the metabolic syndrome in the absence of established hypertension and diabetes: A community-based study
Pai-Feng Hsua, Shao-Yuan Chuangb, Hao-Min Chengc, Shih-Tzer Tsaic, Pesus Choue, f and Chen-Huan Chenc, d, e, g, h, , aDepartment of Health I-Lan Hospital, I-Lan, TaiwanbInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwancDepartment of Medicine, Taipei Veterans General Hospital, Taipei, TaiwandDepartment of Research and Education, Taipei Veterans General Hospital, Taipei, TaiwaneInstitute of Public Health, National Yang-Ming University, Taipei, TaiwanfCommunity Medicine Research Center, National Yang-Ming University, Taipei, TaiwangCardiovascular Research Center, National Yang-Ming University, Taipei, TaiwanhDepartment of Social Medicine, National Yang-Ming University, Taipei, Taiwan Received 18 September 2007; accepted 28 September 2007. Available online 14 November 2007.
Initiator
Prod / Activ Increased
Prod / Activ Decreased
Jnl / Vol / Pg
Author / Yr
Misc / Vol / Ed
Obesity
sI-CAM-1/insulin resistance/metab syndrome ?
life
Metab /51/75
Straczkowski,M/02
METABOLIC SYNDROME :Note that only atherogenesis is missing AND I-CAM elevates this
ED/
hypoganadism
metabolic syndrome/type 2 diabetes/cardiovascular disease
Increasing evidence indicates that both disorders have important associations with the metabolic syndrome, type 2 diabetes, and cardiovascular disease
eplerenone/MR blocker
normal kidney function/decreased nuclear MR expression/aldosterone effector kinase/Sgk1 in the kidney/diminished gene expressions/transforming growth factor- 1/plasminogen activator inhibitor-1/enhanced
TGf/protein wasting/podocyte damage/nuclear MR expression/aldosterone effector kinase/Sgk1 in the kidney/diminished gene expressions/transforming growth factor- 1/plasminogen activator inhibitor-1/enhanced
HYPERTENSION/09/1058/
Miki Nagase/Hiromitsu Matsui/Shigeru Shibata/Takanari Gotoda/Toshiro Fujita07
SHR/NDmcr-cp/SHR/cp/rat model/metabolic syndrome/mineralocorticoid receptor/MR/antagonist eplerenone/dramatically ameliorated salt-induced proteinuria
Initiator
Prod / Activ inc
Prod / Activ dec
Jnl / Vol / Pg
Author / Yr
Misc / Vol / Ed
METABOLIC SYNDROME
sI-CAM-1/insulin resistance /atherogenesis
NORMAL BMI/ normal abdominal circumference
jnl of AMIE/1/10
peters, a/05
surmised from this study: Straczkowski,M/02 Metab /51/75
Initiator
Prod / Activ inc
Prod / Activ dec
Jnl / Vol / Pg
Author / Yr
Misc / Vol / Ed
antiinflammants/metab syndrome
health
metabolic syndrome affected lypopathic pathways
Am J Physiol Renal Physiol
Jesus H. Dominguez/ Pengfei Wu/C. Subah Packer/Constance J Temm/Katherine J. Kelly/07
see metab HD memory/Am J Physiol Renal Physiol 2007
ED/
hypoganadism
metabolic syndrome/type 2 diabetes/cardiovascular disease
Increasing evidence indicates that both disorders have important associations with the metabolic syndrome, type 2 diabetes, and cardiovascular disease
Abstract
Aims/hypothesis
Our aim was to determine the predictive values on the all-cause and cardiovascular mortality and the future risks of hypertension and diabetes of the metabolic syndrome defined by the third report of the National Cholesterol Education Program's Adult Treatment Panel in the absence of established hypertension and diabetes (who may still have elevated blood pressure within 130–139/85–89 mmHg and/or elevated fasting blood glucose within 5.5–6.9 mmol/L (100–125 mg/dL)).
Methods
A community-based population of 11,058 Chinese aged 30 years and above in Kinmen island was followed up for 10.6 years. All-cause and cardiovascular mortality and incidence of hypertension and diabetes mellitus were determined.
Results
The hazard ratios and 95% confidence intervals for all-cause and cardiovascular mortality in subjects with metabolic syndrome but without hypertension and diabetes versus subjects without metabolic syndrome, hypertension, and diabetes, were 0.81 (0.51–1.30) and 0.89 (0.57–1.37) in men, and 1.14 (0.45–2.92) and 0.73 (0.27–2.68) in women, respectively. In the non-diabetic non-hypertensives at baseline, the odds ratios and 95% confidence intervals for predicting hypertension and diabetes for subjects with versus without the metabolic syndrome were 2.25 (1.80–2.82) and 3.12 (2.30–4.24), respectively.
Conclusions/interpretation
In this Chinese population, metabolic syndrome in the absence of hypertension and diabetes was not associated with increased risk of all-cause or cardiovascular mortality. In contrast, the presence of metabolic syndrome predicted future risk of hypertension and diabetes. Therefore, the intervention strategies for subjects with metabolic syndrome may be focused on the prevention of hypertension and diabetes.
Keywords: Mortality; Metabolic syndrome; Hypertension; Diabetes mellitus This work was supported in part by serial grants from the National Science Council (NSC 92-2320-B-010-058-; NSC 93-2314-B-010-040; NSC 94-2314-B-010 -058 -), the intramural grants from the Taipei Veterans General Hospital (Grant No.93-198C), and grants in aid from the Research Foundation of Cardiovascular Medicine (91-02-032, 93-02-014), Taipei, Taiwan, ROC.
Product/Activity
Increased
Product/Activity Decreased
Journal/Volume /Page
Author/Year
metab syndrome/cure /prevention of/ DM/HTN
life
death
Diabetes Research andClinical Practice/Volume 79/Issue 3/Pages 461-467
Pai-Feng Hsua/Shao-Yuan Chuang/Hao-Min Cheng/08
Diabetes Research and Clinical Practice Volume 79, Issue 3, March 2008, Pages 461-467
Clinical significance of the metabolic syndrome in the absence of established hypertension and diabetes: A community-based study
Pai-Feng Hsua, Shao-Yuan Chuangb, Hao-Min Chengc, Shih-Tzer Tsaic, Pesus Choue, f and Chen-Huan Chenc, d, e, g, h, , aDepartment of Health I-Lan Hospital, I-Lan, TaiwanbInstitute of Biomedical Sciences, Academia Sinica, Taipei, TaiwancDepartment of Medicine, Taipei Veterans General Hospital, Taipei, TaiwandDepartment of Research and Education, Taipei Veterans General Hospital, Taipei, TaiwaneInstitute of Public Health, National Yang-Ming University, Taipei, TaiwanfCommunity Medicine Research Center, National Yang-Ming University, Taipei, TaiwangCardiovascular Research Center, National Yang-Ming University, Taipei, TaiwanhDepartment of Social Medicine, National Yang-Ming University, Taipei, Taiwan Received 18 September 2007; accepted 28 September 2007. Available online 14 November 2007.
Initiator
Prod / Activ Increased
Prod / Activ Decreased
Jnl / Vol / Pg
Author / Yr
Misc / Vol / Ed
Obesity
sI-CAM-1/insulin resistance/metab syndrome ?
life
Metab /51/75
Straczkowski,M/02
METABOLIC SYNDROME :Note that only atherogenesis is missing AND I-CAM elevates this
ED/
hypoganadism
metabolic syndrome/type 2 diabetes/cardiovascular disease
Increasing evidence indicates that both disorders have important associations with the metabolic syndrome, type 2 diabetes, and cardiovascular disease
eplerenone/MR blocker
normal kidney function/decreased nuclear MR expression/aldosterone effector kinase/Sgk1 in the kidney/diminished gene expressions/transforming growth factor- 1/plasminogen activator inhibitor-1/enhanced
TGf/protein wasting/podocyte damage/nuclear MR expression/aldosterone effector kinase/Sgk1 in the kidney/diminished gene expressions/transforming growth factor- 1/plasminogen activator inhibitor-1/enhanced
HYPERTENSION/09/1058/
Miki Nagase/Hiromitsu Matsui/Shigeru Shibata/Takanari Gotoda/Toshiro Fujita07
SHR/NDmcr-cp/SHR/cp/rat model/metabolic syndrome/mineralocorticoid receptor/MR/antagonist eplerenone/dramatically ameliorated salt-induced proteinuria
Initiator
Prod / Activ inc
Prod / Activ dec
Jnl / Vol / Pg
Author / Yr
Misc / Vol / Ed
METABOLIC SYNDROME
sI-CAM-1/insulin resistance /atherogenesis
NORMAL BMI/ normal abdominal circumference
jnl of AMIE/1/10
peters, a/05
surmised from this study: Straczkowski,M/02 Metab /51/75
Initiator
Prod / Activ inc
Prod / Activ dec
Jnl / Vol / Pg
Author / Yr
Misc / Vol / Ed
antiinflammants/metab syndrome
health
metabolic syndrome affected lypopathic pathways
Am J Physiol Renal Physiol
Jesus H. Dominguez/ Pengfei Wu/C. Subah Packer/Constance J Temm/Katherine J. Kelly/07
see metab HD memory/Am J Physiol Renal Physiol 2007
ED/
hypoganadism
metabolic syndrome/type 2 diabetes/cardiovascular disease
Increasing evidence indicates that both disorders have important associations with the metabolic syndrome, type 2 diabetes, and cardiovascular disease
Abstract
Aims/hypothesis
Our aim was to determine the predictive values on the all-cause and cardiovascular mortality and the future risks of hypertension and diabetes of the metabolic syndrome defined by the third report of the National Cholesterol Education Program's Adult Treatment Panel in the absence of established hypertension and diabetes (who may still have elevated blood pressure within 130–139/85–89 mmHg and/or elevated fasting blood glucose within 5.5–6.9 mmol/L (100–125 mg/dL)).
Methods
A community-based population of 11,058 Chinese aged 30 years and above in Kinmen island was followed up for 10.6 years. All-cause and cardiovascular mortality and incidence of hypertension and diabetes mellitus were determined.
Results
The hazard ratios and 95% confidence intervals for all-cause and cardiovascular mortality in subjects with metabolic syndrome but without hypertension and diabetes versus subjects without metabolic syndrome, hypertension, and diabetes, were 0.81 (0.51–1.30) and 0.89 (0.57–1.37) in men, and 1.14 (0.45–2.92) and 0.73 (0.27–2.68) in women, respectively. In the non-diabetic non-hypertensives at baseline, the odds ratios and 95% confidence intervals for predicting hypertension and diabetes for subjects with versus without the metabolic syndrome were 2.25 (1.80–2.82) and 3.12 (2.30–4.24), respectively.
Conclusions/interpretation
In this Chinese population, metabolic syndrome in the absence of hypertension and diabetes was not associated with increased risk of all-cause or cardiovascular mortality. In contrast, the presence of metabolic syndrome predicted future risk of hypertension and diabetes. Therefore, the intervention strategies for subjects with metabolic syndrome may be focused on the prevention of hypertension and diabetes.
Keywords: Mortality; Metabolic syndrome; Hypertension; Diabetes mellitus This work was supported in part by serial grants from the National Science Council (NSC 92-2320-B-010-058-; NSC 93-2314-B-010-040; NSC 94-2314-B-010 -058 -), the intramural grants from the Taipei Veterans General Hospital (Grant No.93-198C), and grants in aid from the Research Foundation of Cardiovascular Medicine (91-02-032, 93-02-014), Taipei, Taiwan, ROC.
No comments:
Post a Comment